|Ms. Alison Silva MA, MS||Chief Exec. Officer, Pres and Director||68.76k||N/A||N/A|
|Mr. Eugene Francis Kelly||Chief Financial Officer||N/A||N/A||N/A|
|Ms. Debi Sanderson MBA||Director of Resourcing & Operations||N/A||N/A||N/A|
|Dr. Richard T. Ho M.D., Ph.D.||Chief Scientific Officer||N/A||N/A||54|
|Mr. Paul Papi||VP of Investor Relations||N/A||N/A||N/A|
Critical Outcome Technologies Inc., a clinical stage biopharmaceutical company, develops therapies for the treatment of cancer in Canada. The companys proprietary artificial intelligence platform, CHEMSAS, utilizes a series of predictive computer models to identify compounds from disease specific drug discovery through chemical optimization and preclinical testing. Its lead compound is COTI-2, a novel small molecule activator of misfolded mutant p53 proteins, which is in Phase I clinical trial for the treatment of gynecologic cancers, including ovarian, cervical, and endometrial cancers. The company also develops drug candidates for the treatment of acute myelogenous leukemia, colorectal cancer, small cell lung cancer, multiple sclerosis, and Alzheimers disease; and HIV integrase inhibitors. Critical Outcome Technologies Inc. was founded in 1999 and is based in London, Canada.
Critical Outcome Technologies Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.